Healthcare provider profile · identity verified

Jason Ehrlich, MD

Internal Medicine · GREAT NECK, NY · NPI 1649340092

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	698	230
Amlodipine Besylate	Amlodipine Besylate	472	144
Metformin Hcl	Metformin Hcl	319	105
Lisinopril	Lisinopril	279	87
Losartan Potassium	Losartan Potassium	277	88
Levothyroxine Sodium	Levothyroxine Sodium	212	54
Rosuvastatin Calcium	Rosuvastatin Calcium	202	71
Jardiance	Empagliflozin	188	47
Famotidine	Famotidine	182	46
Metoprolol Succinate	Metoprolol Succinate	163	55
Gabapentin	Gabapentin	162	55
Pantoprazole Sodium	Pantoprazole Sodium	162	52
Omeprazole	Omeprazole	158	50
Eliquis	Apixaban	149	34
Ozempic	Semaglutide	134	37
Hydrochlorothiazide	Hydrochlorothiazide	127	40
Albuterol Sulfate Hfa	Albuterol Sulfate	116	40
Carvedilol	Carvedilol	112	31
Metoprolol Tartrate	Metoprolol Tartrate	112	31
Fluticasone Propionate	Fluticasone Propionate	111	36
Furosemide	Furosemide	106	31
Tamsulosin Hcl	Tamsulosin Hcl	96	31
Warfarin Sodium	Warfarin Sodium	92	21
Januvia	Sitagliptin Phosphate	81	25
Farxiga	Dapagliflozin Propanediol	78	22
Simvastatin	Simvastatin	75	23
Trulicity	Dulaglutide	75	21
Torsemide	Torsemide	74	15
Diclofenac Sodium	Diclofenac Sodium	67	26
Metformin Hcl Er	Metformin Hcl	67	22
Pravastatin Sodium	Pravastatin Sodium	54	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	53	21
Alcohol Prep Pads	Alcohol Antiseptic Pads	52	18
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	52	21
Chlorthalidone	Chlorthalidone	49	19
Rybelsus	Semaglutide	49	suppressed
Sertraline Hcl	Sertraline Hcl	49	19
Entresto	Sacubitril/Valsartan	47	12
Clopidogrel	Clopidogrel Bisulfate	46	19
Escitalopram Oxalate	Escitalopram Oxalate	46	11
Ezetimibe	Ezetimibe	43	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	42	19
Allopurinol	Allopurinol	41	11
Spironolactone	Spironolactone	41	12
Trazodone Hcl	Trazodone Hcl	41	suppressed
Enalapril Maleate	Enalapril Maleate	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	15
Levetiracetam	Levetiracetam	35	suppressed
Hydralazine Hcl	Hydralazine Hcl	34	15
Nifedipine Er	Nifedipine	34	14
Alendronate Sodium	Alendronate Sodium	33	13
Atenolol	Atenolol	33	11
Glipizide Er	Glipizide	33	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	32	suppressed
Labetalol Hcl	Labetalol Hcl	31	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	31	suppressed
Single Use Swab	Alcohol Antiseptic Pads	28	11
Lidocaine	Lidocaine	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Pregabalin	Pregabalin	26	suppressed
Ramipril	Ramipril	25	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	25	suppressed
Finasteride	Finasteride	24	12
Latanoprost	Latanoprost	24	suppressed
Baclofen	Baclofen	23	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Meclizine Hcl	Meclizine Hcl	20	suppressed
Mometasone Furoate	Mometasone Furoate	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Propranolol Hcl Er	Propranolol Hcl	20	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	20	suppressed
Clonazepam	Clonazepam	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Repaglinide	Repaglinide	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Novolog Flexpen	Insulin Aspart	17	suppressed
Cilostazol	Cilostazol	16	suppressed
Glipizide	Glipizide	16	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	16	suppressed
Lactulose	Lactulose	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Vascepa	Icosapent Ethyl	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Prednisone	Prednisone	15	11
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Digoxin	Digoxin	14	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Oxycodone Hcl	Oxycodone Hcl	13	suppressed
Bumetanide	Bumetanide	12	suppressed
Colchicine	Colchicine	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Zaleplon	Zaleplon	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Alprazolam	Alprazolam	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Diazepam	Diazepam	11	suppressed
Eplerenone	Eplerenone	11	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error